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Supporting Experimental Procedures 
Synthesis of 1  
i. (3S,4R)-4-Methyl-5-hexen-3-ol (4).[1] 
 
To a stirred mixture of potassium tert-butoxide (4.6 g, 41.5 mmol) in THF (15 mL) were added 
trans-2-butene (7.2 mL, 80 mmol) and n-butyllithium [26.0 mL (1.6 M in hexane), 41.5 mmol]. 
After the solution was stirred at -78 °C for 30 min, it was added to a solution of B-
methoxydiisopinocampheylborane [50 mL (1.0 M in ether), 50 mmol] dropwise. The resultant 
solution was stirred at -78 °C for 30 min, and BF3
.OEt2 (7.0 mL, 56.0 mmol) and propanal (4.3 mL, 
58.5 mmol) was successively added dropwise at -78 °C. The solution was stirred at -78 °C for 3 h 
and then treated with 3 N NaOH (30 mL) and 30 % H2O2 (12 mL). The mixture was heated to reflux 
for 1 h before it was extracted with ether (3 × 40 mL). The organic phase was separated and washed 
with water (100 mL) and brine (100 mL). The organic layer was dried (MgSO4) and concentrated. 
Purification by flash chromatography (hexane/EtOAc = 7:1) offered the alcohol 4 (2.8 g, 61%) as a 
colorless oil: [α]30D +12.5 (c 0.88, CHCl3); IR (film) max 3363, 2963, 2932, 2875, 1640, 1460, 1109, 
968 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.76 (ddd, J = 8.3, 11.3, 16.3 Hz, 1H), 5.10 (m, 2H), 3.33 
(m, 1H), 2.22 (m, 1H), 1.60 (m, 1H), 1.40 (m, 1H), 1.03 (d, J = 6.8 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 140.4, 116.2, 76.0, 43.7, 27.0, 16.3, 10.0; HR-ESI-MS m/z 137.0936 
[M + Na]+ (calcd for C7H14ONa, 137.0937). 
 
ii. (3S,4R)-3-Methanesulfonyloxy-4-methyl-5-hexen (5). 
 
To a stirred solution of alcohol 4 (780 mg, 6.8 mmol) in CH2Cl2 (25 mL) were added 
triethylamine (3.3 mL, 23.9 mmol) and methanesulfonyl chloride (1.6 mL, 20.5 mmol) at 0 °C. The 
reaction mixture was stirred for 20 min at 0 °C before it was warmed to room temperature. After 
additional stirring for 2 h at room temperature, water (30 mL) was added, and the mixture was 
extracted with CH2Cl2 (3 × 30 mL). The organic layer was separated, dried (MgSO4), and 
concentrated. Purification by flash chromatography (hexane/EtOAc = 7:1) offered the desired 
methanesulfonate ester 5 (1.16 g, 89%) as a colorless oil. [α]29D 2.25 (c 1.59, CHCl3); IR (film) max 
2971, 2879, 1641, 1463, 1418, 1341, 1175, 1048, 973 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.74 (m, 
1H), 5.11 (m, 2H), 4.62 (ddd, J = 4.9, 6.2, 11.0 Hz, 1H), 3.02 (s, 3H), 2.60 (m, 1H), 1.71 (m, 2H), 
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1.10 (d, J = 6.9 Hz, 3H), 0.98 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 138.4, 116.5, 88.1, 
41.1, 38.7, 24.6, 15.7, 9.7; HR-ESI-MS m/z 215.0711 [M + Na]+ (calcd for C8H16O3SNa, 215.0712). 
 
iii. (3R,4R)-3-Amine-4-methyl-5-hexene (2). 
 
To a solution of methanesulfonate ester 5 (1.16 g, 6.03 mmol) in HMPA (10 mL) was added 
sodium azide (1.57 g, 24.1 mmol) at room temperature. The solution was heated to 40 °C and stirred 
at this temperature for 2 h. After the solution was cooled down to room temperature, water (20 mL) 
was added. The mixture was extracted with ether (3 × 20 mL), and the organic phase was separated 
and washed with water (40 mL) and brine (40 mL). The organic layer was dried (MgSO4), and 
concentrated. The residue was dissolved in THF (30 mL) and added slowly in portions to a solution 
of LiAlH4 (7.2 mL (1.0 M in THF), 7.2 mmol) and ethanol (0.42 mL, 7.2 mmol) in THF (10 mL) at 
0 °C. The solution was stirred for 10 min at 0 °C before it was warmed to room temperature. After 
additional stirring for 2 h at room temperature, aqueous saturated Na2SO4 (0.6 mL), and anhydride 
Na2SO4 (1.0 g) were added to the solution. The mixture was concentrated and purified by flash 
chromatography (methanol/EtOAc = 1:10) to give the desired amine 2 (670 mg, 98%) as a colorless 
liquid: [α]29D +18.8 (c 1.56, CHCl3); IR (film) max 3341, 2936, 1640, 1544, 1460, 1380, 1053 cm-1; 
1H NMR (400 MHz, CDCl3) δ 5.77 (ddd, J = 7.3, 9.9, 17.5 Hz, 1H), 4.99 (m, 2H), 2.55 (ddd, J = 4.7, 
4.7, 8.9 Hz, 1H), 2.29 (br s, 2H), 2.18 (m, 1H), 1.48 (m, 1H), 1.24 (m, 1H), 0.94 (d, J = 6.9 Hz, 3H), 
0.89 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 141.5, 114.6, 56.7, 42.5, 26.8, 14.1, 10.8; 
HR-ESI-MS m/z 114.1279 [M + H]+ (calcd for C7H16N, 114.1277). 
 
iv. (2R,3S,4S,6R)-3,7-Bis(tert-butyldimethylsilyloxy)-2,4,6-trimethyl-N-((3R,4R)-4-
methylhex-5-en-3-yl)heptanamide (6). 
 
To a solution of carboxylic acid 3 (450 mg, 1.04 mmol)[2] in CH2Cl2 (10 mL) at 0 °C was added 
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DIPEA (233 µL, 1.35 mmol), HOBt (182 mg, 1.35 mmol), and EDC.HCl (259 mg, 1.35 mmol). The 
mixture was stirred for 15 min at 0 °C, and a solution of amine 2 (235 mg, 2.08 mmol) in CH2Cl2 (1 
mL) was added. The mixture was stirred for 2 h at 0 °C before it was warmed to room temperature. 
After additional stirring for 16 hr at room temperature, saturated NH4Cl (10 mL) was added to the 
solution, and the mixture was extracted with CH2Cl2 (3 × 10 mL). The organic layer was separated, 
dried (MgSO4), and concentrated. Purification by flash chromatography (hexane/EtOAc = 7:1) 
offered the desired amide 6 (445 mg, 81%) as a colorless oil: [α]25D +4.6 (c 1.41, CHCl3); IR (film) 
max 3306, 2958, 2858, 1639, 1540, 1464, 1383, 1256, 1074, 913 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 5.73 (ddd, J = 7.9, 9.8, 17.7 Hz, 1H), 5.49 (bd, J = 9.4 Hz, 1H), 5.01 (m, 2H), 3.81 (m, 1H), 3.49 
(dd, J = 4.8, 9.7 Hz, 1H), 3.24 (dd, J = 7.2, 9.7 Hz, 1H), 2.40 (m, 1H), 2.31 (m, 1H), 1.77~1.57 (m, 
4H), 1.47 (m, 1H), 1.21 (m, 1H), 1.15 (d, J = 7.1 Hz, 3H), 1.02 (d, J = 6.9 Hz, 3H), 0.89 (m, 27H), 
0.05 (m, 12H); 13C NMR (100 MHz, CDCl3) δ 174.9, 140.6, 115.2, 77.6, 67.9, 54.0, 44.8, 42.0, 36.5, 
36.2, 33.8, 26.0, 25.9, 24.4, 18.4, 18.3(×2), 16.9, 16.3, 15.7, 10.7, -4.1, -5.4; HR-ESI-MS m/z 
550.4087 [M + Na]+ (calcd for C29H61NO3Si2Na, 550.4082). 
 
v. (2R,3S,4S,6R)-3-(tert-Butyldimethylsilyloxy)-7-hydroxy-2,4,6-trimethyl-N-((3R,4R)-4-
methylhex-5-en-3-yl)heptanamide (7). 
 
Amide 6 (445 mg, 0.84 mmol) was dissolved in methanol (10 mL) at 0 °C. To this solution was 
added DL-10-camphorsulfonic acid (58 mg, 0.25 mmol). The resulting solution was stirred at 0 °C 
for 1 h. The reaction was terminated by the addition of Et3N (200 μL, 1.43 mmol). After the solution 
was concentrated, purification by flash chromatography (hexane/EtOAc = 4:1) gave the desired 
primary alcohol 7 (297 mg, 86 %) as a colorless oil: [α]31D +6.8 (c 1.05, CHCl3); IR (film) max 3298, 
2960, 2931, 1643, 1546, 1461, 1380, 1254, 1069, 911 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.72 (m, 
1H), 5.58 (bd, J = 9.3 Hz, 1H), 5.01 (m, 2H), 3.77 (m, 2H), 3.54 (dd, J = 4.3, 10.9 Hz, 1H), 3.33 (dd, 
J = 5.4, 10.8 Hz, 1H), 2.76 (bs, 1H), 2.43 (m, 1H), 2.32 (m, 1H), 1.81 (m, 1H), 1.63 (m, 3H), 1.24 (m, 
1H), 1.16 (d, J = 7.0 Hz, 3H), 1.03 (d, J = 6.9 Hz, 3H), 0.93 (m, 15H), 0.86 (t, J = 7.4 Hz, 3H), 0.08 
(s, 6H); 13C NMR (100 MHz, CDCl3) δ 175.4, 140.5, 115.5, 77.7, 66.6, 54.3, 45.3, 41.8, 35.2, 34.8, 
32.8, 26.0, 24.2, 18.3, 17.7, 16.6, 16.1, 10.5, -4.0, -4.2; HR-ESI-MS m/z 436.3219 [M + Na]+ (calcd 
for C23H47NO3SiNa, 436.3217). 
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vi. (2R,3S,4S,6R)-3-((tert-butyldimethylsilyl)oxy)-2,4,6-trimethyl-N-((3R,4R)-4-methylhex-5-
en-3-yl)-7-oxoheptanamide (8). 
 
To a solution of alcohol 7 (297 mg, 0.72 mmol) in CH2Cl2 (20 mL) was added Dess-Martin 
periodinane (DMP) (611 mg, 1.44 mmol). The resultant solution was stirred for 2 h at room 
temperature before saturated NaHCO3 (10 mL) and Na2SO4 (5 mL) were added. The mixture was 
extracted with CH2Cl2 (3 × 15 mL), and the organic layer was separated, dried (MgSO4), and 
concentrated. Purification by flash chromatography (hexane/EtOAc = 5:1) offered the desired 
aldehyde 8 (246 mg, 83 %) as a colorless liquid: [α]29D +29.4 (c 1.70, CHCl3); IR (film) max 3313, 
2931, 1726, 1641, 1537, 1461, 1254, 1066, 836 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.59 (d, J = 1.9 
Hz, 1H), 5.71 (m, 1H), 5.64 (bd, J = 9.4 Hz, 1H), 5.01 (m, 2H), 3.80 (m, 2H), 2.46 (m, 2H), 2.31 (m, 
1H), 1.93 (ddd, J = 3.5, 9.5, 13.8 Hz, 1H), 1.59 (m, 3H), 1.25 (m, 1H), 1.16 (d, J = 7.1 Hz, 3H), 1.11 
(d, J = 7.2 Hz, 3H), 0.99 (d, J = 6.9 Hz, 3H), 0.93 (m, d, J = 6.9 Hz, 3H), 0.88 (m, 12H), 0.08 (s, 3H), 
0.07 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 205.4, 174.9, 140.8, 115.0, 54.2, 45.4, 44.3, 41.8, 36.2, 
32.8, 26.1, 24.5, 18.3, 17.2, 16.2, 16.0, 14.9, 10.7, -3.9, -4.0; HR-ESI-MS m/z 434.3062 [M + Na]+ 
calcd for C23H45NO3SiNa, 434.3061). 
 
vii. (2R,3S,4S,6R)-3-((tert-butyldimethylsilyl)oxy)-2,4,6-trimethyl-N-((3R,4R)-4-methylhex-5-
en-3-yl)-7-oxonon-8-enamide (9). 
   
To a stirred solution of aldehyde 8 (246 mg, 0.60 mmol) in THF (10 mL) was added 
vinylmagnesium bromide (1 M in THF) (1.20 mL, 1.20 mmol) at 0 °C. After 1 h, the solution was 
diluted by adding Et2O (10 mL), and then a saturated aqueous NH4Cl solution (10 mL) was added. 
The organic layers were separated, and the aqueous layer was extracted with ether (3 × 10 mL). The 
organic solutions were combined, dried (MgSO4), and concentrated. Purification of the residue by 
flash chromatography (hexane/EtOAc = 5:1) afforded the desired vinyl alcohol (201 mg, 76 %) as a 
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colorless oil. 
The vinyl alcohol (201 mg, 0.46 mmol) was dissolved in CH2Cl2 (10 mL), Dess-Martin 
periodinane (DMP) (390 mg, 0.92 mmol) was added, and the resultant solution was stirred for 2 h at 
room temperature. After the reaction was complete, aqueous saturated NaHCO3 (10 mL) and Na2SO4 
(5 mL) were added. The mixture was extracted with CH2Cl2 (3 × 10 mL). The organic layer was 
separated, dried (MgSO4), and concentrated. Purification by flash chromatography (hexane/EtOAc = 
5:1) offered the desired vinyl ketone 9 (145 mg, 72 %) as a colorless liquid: [α]28D +32.4 (c 0.53, 
CHCl3); IR (film) max 3302, 2928, 2358, 1726, 1645, 1532, 1461, 1379, 1254, 1064, 910 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 6.44 (dd, J = 10.4, 17.5 Hz, 1H), 6.28 (dd, J = 1.4, 17.5 Hz, 1H), 5.80 (m, 
2H), 5.67 (ddd, J = 8.0, 10.3, 17.2 Hz, 1H), 4.98 (m, 2H), 3.74 (m, 2H), 2.93 (m, 1H), 2.61 (m, 1H), 
2.21 (m, 1H), 2.02 (m, 1H), 1.27 (m, 2H), 1.15 (m, 6H), 0.91 (m, 18H), 0.08 (s, 3H), 0.07 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 204.7, 175.4, 141.1, 135.6, 128.3, 114.7, 77.6, 54.4, 45.7, 42.1, 41.2, 
36.2, 34.1, 26.2, 24.8, 18.9, 18.4, 17.8, 16.6, 16.0, 10.6, -3.7, -3.8; HR-ESI-MS m/z 460.3219 [M + 
Na]+ (calcd for C25H47NO3SiNa, 460.3217). 
 
viii. (E)-(3R,4S,5S,7R,11R,12R)-4-((tert-butyldimethylsilyl)oxy)-12-ethyl-3,5,7,11-
tetramethylazacyclododec-9-ene-2,8-dione (10). 
 
Vinyl ketone 9 (145 mg, 0.33 mmol) was dissolved in CH2Cl2 (20 mL) at room temperature. 
Grubbs’ catalyst (second generation) (56 mg, 20 mol%) was added, producing a light brown solution 
which was stirred for 19 h at room temperature. The mixture was then concentrated, and purification 
of this residue by flash chromatography (hexane/EtOAc = 4:1) afforded the product 10 (83 mg, 61 %) 
as a white solid: mp : 184-186 °C; [α]29D +35.9 (c 0.69, CHCl3); IR (film) max 3300, 2928, 1735, 
1691, 1632, 1544, 1462, 1379, 1255, 1092, 1050, 1023, 979 cm-1; 1H NMR (400 MHz, CDCl3) δ 
6.73 (dd, J = 5.3, 15.9 Hz, 1H), 6.32 (dd, J = 1.3, 15.9 Hz, 1H), 5.23 (bd, J = 10.3 Hz, 1H), 4.09 (m, 
1H), 3.64 (d, J = 8.8 Hz, 1H), 2.73 (m, 1H), 2.52 (m, 1H), 2.30 (m, 1H), 1.48 (m, 3H), 1.36 (m, 2H), 
1.21 (d, J = 6.9 Hz, 6H), 1.00 (d, J = 7.0 Hz, 3H), 0.95 (m, 3H), 0.92 (m, 3H), 0.90 (s, 9H), 0.08 (s, 
3H), 0.07 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 205.1, 174.8, 147.3, 125.6, 79.9, 77.2, 50.5, 46.8, 
44.7, 37.7, 34.5, 33.8, 29.7, 26.6, 26.3, 18.5, 17.8, 11.0, 9.6, -3.2, -3.5; HR-ESI-MS m/z 432.2903 [M 
+ Na]+ (calcd for C23H43NO3SiNa, 432.2904). 
 
ix. (3R,4S,5S,7R,9E,11R,12R)-12-ethyl-4-hydroxy-3,5,7,11-tetramethylazacyclododec-9-ene-
2,8-dione [aza-10-deoxymethynolide, AZDM, 1]. 
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To a stirred solution of product 10 (83 mg, 0.20 mmol) in dry THF (10 mL) at room temperature 
was added 1.0 M TBAF (400 µL, 0.40 mmol). After 3 h, the reaction mixture was concentrated. 
Purification by flash chromatography (hexane/EtOAc = 1:2) afforded alcohol 1 (46 mg, 78 %) as a 
white solid: mp: 166-168 °C ; [α]28D +42.8 (c 0.31, CHCl3); IR (film) max 3280, 2925, 2854, 1740, 
1687, 1631, 1545, 1459, 1382, 1254, 1152, 979 cm-1; 1H NMR (500 MHz, CD3OD) δ 6.72 (dd, J = 
16, 6Hz, 1H), 6.42 (d, J = 16 Hz, 1H), 4.00 (m, 1H), 3.42 (d, J = 10 Hz, 1H), 2.73 (m, 1H), 2.50 (m, 
1H), 2.48 (m, 1H), 1.65 (t, J = 13.5 Hz, 1H), 1.53 (m, 2H), 1.35 (td, J = 12.5, 4 Hz, 1H), 1.29 (m, 
1H), 1.25 (d, J = 7.0 Hz, 3H), 1.23 (d, J = 7.0 Hz, 3H), 1.06 (d, J = 6.5 Hz, 3H), 0.94 (d, J = 6.5 Hz, 
3H), 0.93 (t, J = 7.5 Hz, 3H); 13C NMR (125 MHz, CD3OD) δ 207.8, 177.9, 149.7, 126.5, 79.2, 52.0, 
46.7, 45.8, 39.9, 34.7, 34.3, 27.2, 17.8, 17.8, 17.7, 11.6, 10.1; (+)-ESI-MS m/z 318.0 [M + Na]+, 
313.0 [M + NH4]
+, 296.0 [M + H]+, 277.9 [M + H – H2O]+, 259.9 [M + H – 2H2O]+; HR-ESI-MS 
m/z 318.2041 [M + Na]+ (calcd for C17H29NO3Na, 318.2040). 
 
Construction of expression plasmids and S. venezuelae mutant strains 
DNA fragments containing several deoxysugar biosynthetic genes were amplified by 
polymerase chain reaction (PCR) with specific deoxyoligonucleotide primers and template DNAs.[3] 
PCR was performed using Pfu polymerase (Fermentas GmbH, St. Leon-Rot, Germany) under the 
manufacturer’s recommended conditions. The genes involved in the glycosylation of aza-10-
deoxymethynolide (AZDM; 1) with various deoxysugars were cloned into the replicative plasmid 
pSE34. To efficiently construct a plasmid carrying different genes, the PacI/XbaI fragment 
containing one gene was ligated to PacI/SpeI-digested Litmus28 carrying the other genes. This 
procedure was recursively repeated until all genes responsible for the conversion of 1 to its 
glycosylated derivatives were combined in Litmus28 and then were moved into pSE34 digested with 
PacI/XbaI. See Table S1 for the combined gene organizations. Construction of pDDSS, pDQNV, 
pLRAM2, and pLOLV2 was previously described.[3] These plasmids were separately introduced into 
S. venezuelae YJ028[4] and the resulting recombinants were used for in vivo glycosylation of the 
synthesized macrolactam 1.  
 
Cytotoxicity assay of 11 and 12 
The cytotoxicity test was performed with human embryonic kidney cell line HEK 293 according 
to a previously published method with modification.[5] HEK 293 cells were seeded at 1 × 106 cells 
into each well of 96-well flat-bottomed microtitre plates with DMEM medium supplemented with 
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fetal bovine serum (10%), penicillin (100 U∙mL-1) and streptomycin (100 g∙mL-1). And the 
microplates were kept in incubator for 24 h (37 °C, 5% CO2). Before treatment, all the medium were 
exchanged with the fresh supplemented medium. The tested compounds dissolved in DMSO were 
treated at concentration of 100, 50, 25, 12.5, 6.25, 3.13 and 1.56 mol in triplicate. The microplates 
were kept in incubator for 24 h (37 °C, 5% CO2). 20 L of the MTT solution in DPBS (5 mg∙mL-1) 
were added into each well of the microplate and the microplate were kept in incubator for 4 h (37 °C, 
5% CO2). All the medium were exchaged with 100 L DMSO and the optical density were recorded 
at 570 nm. Erythromycin was treated as a positive control (IC50 = 65.5 mol).  
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Table S1. Biosynthetic gene sets in the engineered strains of S. venezuelae and their products. 
Plasmid Combination of genes Products 
pLRHAM2 desVIII-desVII-desIII-desIV-oleL-oleU 11, 12  
pDQNV desVIII-desVII-desIII-desIV 12 
pDDSS desVIII-desVII-desIII-desIV-desI-desII-desV-desVI 12, 13, 14, 15, 16 
pLOLV2 desVIII-desVII-desIII-desIV-oleV-oleW-oleL-oleU 12, 17, 18 
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Table S2. 13C- and 1H-NMR data of isolated macrolactam glycosides in CD3OD at 125 MHz and 500 MHz, respectively. 
 
No.            11           12a            13           16           17 
  C  H (m, J in Hz)  C  H (m, J in Hz)  C  H (m, J in Hz)  C  H (m, J in Hz)  C  H (m, J in Hz) 
1 177.4  177.8  177.8  177.7  177.6  
2 46.1 2.69 (dq, 10.0, 7.0) 46.1 2.76 (dq, 9.9, 6.3) 46.2 2.76 (dq, 9.5, 6.5) 46.1 2.76 (m, 9.5, 6.5) 45.9 2.68 (dq, 10.0, 7.0) 
3 91.2 3.48 (d, 9.5) 87.7 3.54 (d, 9.9) 87.5 3.54 (m, 8.5)b 88.4 3.59 (d, 10.0) 88.5 3.53 (d, 10.0) 
4 34.3 1.33 (m) 34.2 1.32 (overlapped) 34.3 1.29 (m)b 34.3 1.30 (m) 34.2 1.25 (overlapped) 
5 35.3 1.71 (t, 13.0)    
1.41 (td, 13.0, 3.0) 
35.5 1.71 (br t, 12.6) 
1.41 (td, 12.6, 3.6) 
35.5 1.72 (t, 12.5)  
1.42 (td, 12.5, 3.0) 
35.4 1.76 (t, 14.0) 
1.45 (m) 
35.2 1.66 (t, 13.5) 
1.40 (m, 13.5, 4.0) 
6 46.4 2.48 (m) 46.4 2.47 (m) 46.4 2.47 (m) 46.5 2.48 (m) 46.4 2.48 (m) 
7 207.6  207.9  208.0  207.9  207.4  
8 126.5 6.44 (d, 16.0) 126.6 6.44 (d, 15.3) 126.6 6.44 (d, 15.5) 126.6 6.44 (d, 15.5) 126.6 6.44 (d, 16.0) 
9 149.7 6.72 (dd, 15.5, 5.5) 149.5 6.72 (dd, 16.2, 6.3) 149.5 6.72 (dd, 15.5, 5.5) 149.6 6.72 (dd, 16, 5.5) 149.5 6.72 (dd, 16.0, 6.0) 
10 39.6 2.73 (m) 39.7 2.73 (m) 39.7 2.73 (m) 39.7 2.73 (m) 39.6 2.71 (m) 
11 51.9 3.97 (m) 51.9 3.97 (ddd, 9.0, 5.3, 
3.7) 
51.9 3.97 (m) 51.9 3.97 (m)b 51.9 3.96 (m) 
12 27.2 1.52 (m) 27.2 1.52 (m) 27.2 1.52 (m) 27.2 1.52 (m) 27.2 1.52 (m) 
13 11.5 0.93 (t, 7.5) 11.5 0.93 (t, 7.2) 11.5 0.93 (t, 7.0) 11.5 0.93 (t, 7.0) 11.5 0.93 (t, 7.0) 
14 17.7b 1.24 (overlapped)b 17.5 1.34 (d, 7.2) 17.6b 1.34 (d, 7.0) 17.4 1.33 (d) 17.6b 1.22 (d, 6.5) 
15 17.9 1.00 (d, 6.5) 17.9b 0.97 (d, 7.2) 17.9 0.97 (d, 7.0) 18.0 1.04 (d, 7.0) 17.7b 0.98 (d, 6.0) 
16 17.7b 1.23 (overlapped)b 17.7 1.20 (d, 7.2) 17.7b 1.20 (d, 6.5) 17.7 1.23 (d, 6.5) 17.7b 1.21 (d, 7.0) 
17 10.0 1.07 (d, 6.5) 10.0 1.07 (d, 6.3) 10.0 1.07 (d, 6.5) 10.0 1.07 (d, 7.5) 10.0 1.07 (d, 7.0) 
1 105.1 4.67 (br s) 105.1 4.27 (d, 8.1) 105.4 4.20 (d, 7.5) 106.4 4.39 (d, 8.0) 102.7 4.47 (dd, 9.5, 1.5) 
2 72.5b 3.92 (br s) 76.0 3.16 (dd, 8.1, 9.0 ) 77.5 3.05 (t, 8.5) 79.6 3.96 (m)b 40.7 2.17 (ddd, 12.0, 5.5, 
1.5) 
1.43 (m) 
3 72.4b 3.59 (dd, 9.5, 3,0)  78.1 3.28 (t, 9.0) 72.5 3.54 (m, 8.5)b 206.9  72.3 3.48 (ddd, 12.0, 9.0, 
5.5) 
4 73.7 3.40 (t, 9.5) 77.2 2.97 (t, 9.0) 42.2 1.90 (dd, 12.5, 5) 
1.27 (m) 
48.3 2.44 (d, 6.0) 78.5 2.87 (t, 9.0) 
5 70.4 3.71 (dq, 9.5, 7.0) 72.9 3.23 (dq, 9.0, 6.0) 68.8 3.54 (m, 8.5 )b 68.9 3.70 (m, 12.5, 6.5) 73.1 3.17 (m, 9.2, 6.3) 
6 17.6b 1.24 (overlapped)b 18.0b 1.24 (d, 6.3) 21.2 1.19 (d, 6.5) 21.5 1.32 (d) 18.2 1.25 (d, 6.0) 
a 1H- and 13C-NMR spectra were measured at 900 MHz and 225 MHz, respectively. 
b Similar values from the same column may be interchanged. 
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Table S3. Comparison of the productivity of AZDM glycosides and their respective YC-17 
analogues. 
aPreviously reported.[3a] 
 
Sugar macrolactam glycosides (mg L1) YC-17 analoguesa (mg L1) 
L-rhamnosyl 0.58 0.50 
D-quinovosyl 0.16 3.40 
D-desosaminyl trace 1.10 
3-O-demethyl-D-chalcosyl 0.50 not detected 
D-olivosyl 0.26 0.10 
L-olivosyl trace 0.30 
3-keto-4,6-dideoxy-D-glucosyl 0.75 not detected 
N-dedimethyl-N-acetyl-D-desosaminyl trace not detected 
L-digitoxosyl not detected not detected 
D-boivinosyl not detected 0.02 
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Table S4. In vitro antibacterial activities of macrolactam glycosides. 
aE. faecium ATCC 19434 and S. aureus ATCC 25923 are erythromycin-susceptible pathogens and E. 
faecium P00558 and S. aureus P00740 are clinically isolated erythromycin-resistant pathogens. 
No. MIC (µM)a 
E. faecium  
ATCC19434 
E. faecium  
P00558  
S. aureus  
ATCC25923 
S. aureus  
P00740 
11 7.5 30.0 15.0 30.0 
12 7.5 30.0 15.0 15.0 
13 30.0 120.0 60.0 120.0 
16 30.0 120.0 60.0 120.0 
17 30.0 >120.0 60.0 60.0 
Erythromycin 30.0 >120.0 60.0 120.0 
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Table S5. In vitro antibacterial activities of lactams, counterpart lactones, and erythromycin. 
 
 
Sugar 
MIC (µM)a 
macrolactam glycosides  macrolactone glycosidesb 
E. faecium  
ATCC19434 
E. faecium 
P00558  
S. aureus 
ATCC25923 
S. aureus 
P00740 
 E. faecium  
ATCC19434 
E. faecium 
P00558  
S. aureus 
ATCC25923 
S. aureus 
P00740 
L- rhamnosyl 7.5 30.0 15.0 30.0  11.3 5.6 5.6 5.6 
D-quinovosyl 7.5 30.0 15.0 15.0  11.3 11.3 22.6 22.6 
D-olivosyl 30.0 >120.0 60.0 60.0  23.2 46.5 46.5 23.2 
Erythromycin      30.0 >120.0 60.0 120.0 
aE. faecium ATCC 19434 and S. aureus ATCC 25923 are erythromycin-susceptible pathogens and E. faecium P00558 and S. aureus P00740 are clinically 
isolated erythromycin-resistant pathogens.  
bPreviously reported.[3a] 
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Scheme S1. Retrosynthetic analysis of AZDM 1 
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Figure S1. 1H NMR spectrum of 4 in CDCl3 at 400 MHz. 
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Figure S2. 13C NMR spectrum of 4 in CDCl3 at 100 MHz. 
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Figure S3. 1H NMR spectrum of 5 in CDCl3 at 400 MHz. 
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Figure S4. 13C NMR spectrum of 5 in CDCl3 at 100 MHz. 
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Figure S5. 1H NMR spectrum of 2 in CDCl3 at 400 MHz. 
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Figure S6. 13C NMR spectrum of 2 in CDCl3 at 100 MHz. 
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Figure S7. 1H NMR spectrum of 6 in CDCl3 at 400 MHz. 
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Figure S8. 13C NMR spectrum of 6 in CDCl3 at 100 MHz. 
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Figure S9. 1H NMR spectrum of 7 in CDCl3 at 400 MHz. 
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Figure S10. 13C NMR spectrum of 7 in CDCl3 at 100 MHz. 
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Figure S11. 1H NMR spectrum of 8 in CDCl3 at 400 MHz. 
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Figure S12. 13C NMR spectrum of 8 in CDCl3 at 100 MHz. 
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Figure S13. 1H NMR spectrum of 9 in CDCl3 at 400 MHz. 
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Figure S14. 13C NMR spectrum of 9 in CDCl3 at 100 MHz. 
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Figure S15. 1H NMR spectrum of 10 in CDCl3 at 400 MHz. 
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Figure S16. 13C NMR spectrum of 10 in CDCl3 at 100 MHz. 
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Figure S17. ESI-MS/MS spectrum of 1. 
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Figure S18. 1H NMR spectrum of 1 in CD3OD at 500 MHz. 
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Figure S19. 13C NMR spectrum of 1 in CD3OD at 125 MHz. 
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Figure S20. COSY spectrum of 1 in CD3OD at 500 MHz. 
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Figure S21. HSQC spectrum of 1 in CD3OD at 500 MHz. 
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Figure S22. HMBC spectrum of 1 in CD3OD at 500 MHz. 
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Figure S23. ESI-MS/MS spectrum of 11. 
Compound 11 displayed ammonium adduct ion at m/z 459 in the MS spectrum. MS/MS analysis showed the characteristic fragmentation pattern 
with the parent ion at m/z 442 and daughter ion at m/z 296.  
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Figure S24. ESI-MS/MS spectrum of 12. 
Compound 12 revealed proton adduct ion at m/z 442 in the MS spectrum. MS/MS analysis displayed the characteristic fragmentation pattern 
with the daughter ion at m/z 296.  
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Figure S25. ESI-MS/MS spectrum of 13. 
Compound 13 showed sodium adduct ion at m/z 448 in the MS spectrum. MS/MS analysis exhibited the characteristic fragmentation pattern 
with the parent ion at m/z 426 and daughter ion at m/z 296.  
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Figure S26. ESI-MS/MS spectrum of 14. 
Compound 14 exhibited sodium adduct ion at m/z 489 in the MS spectrum. MS/MS analysis displayed the characteristic fragmentation pattern 
with the parent ion at m/z 467 and daughter ions at m/z 296 and m/z 172.  
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Figure S27. ESI-MS/MS spectrum of 15. 
Compound 15 revealed sodium adduct ion at m/z 475 in the MS spectrum. MS/MS analysis exhibited the characteristic fragmentation pattern 
with parent ion at m/z 453 and daughter ions at m/z 296 and m/z 158.  
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Figure S28. ESI-MS/MS spectrum of 16. 
Compound 16 showed ammonium adduct ion at m/z 441 in the MS spectrum. MS/MS analysis displayed the characteristic fragmentation pattern 
with parent ion at m/z 424 and daughter ion at m/z 296.  
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Figure S29. ESI-MS/MS spectrum of 17. 
Compound 17 exhibited ammonium adduct ion at m/z 443 in the MS spectrum. MS/MS analysis displayed the characteristic fragmentation 
pattern with parent ion at m/z 426 and daughter ion at m/z 296. 
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Figure S30. ESI-MS/MS spectrum of 18. 
Compound 18 showed sodium adduct ion at m/z 448 in the MS spectrum. MS/MS analysis exhibited the characteristic fragmentation pattern 
with parent ion at m/z 426 and daughter ion at m/z 296.  
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Figure S31. 1H NMR spectrum of 11 in CD3OD at 500 MHz. 
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Figure S32. 13C NMR spectrum of 11 in CD3OD at 500 MHz. 
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Figure S33. COSY spectrum of 11 in CD3OD at 500 MHz. 
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Figure S34. HSQC spectrum of 11 in CD3OD at 500 MHz. 
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Figure S35. HMBC spectrum of 11 in CD3OD at 500 MHz. 
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Figure S36. NOESY spectrum of 11 in CD3OD at 500 MHz. 
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Figure S37. 1H NMR spectrum of 12 in CD3OD at 900 MHz. 
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Figure S38. 13C NMR spectrum of 12 in CD3OD at 225 MHz. 
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Figure S39. COSY spectrum of 12 in CD3OD at 900 MHz. 
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Figure S40. HSQC spectrum of 12 in CD3OD at 900 MHz. 
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Figure S41. HMBC spectrum of 12 in CD3OD at 900 MHz. 
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Figure S42. NOESY spectrum of 12 in CD3OD at 900 MHz. 
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Figure S43. 1H NMR spectrum of 13 in CD3OD at 500 MHz. 
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Figure S44. 13C NMR spectrum of 13 in CD3OD at 500 MHz. 
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Figure S45. COSY spectrum of 13 in CD3OD at 500 MHz. 
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Figure S46. HSQC spectrum of 13 in CD3OD at 500 MHz. 
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Figure S47. HMBC spectrum of 13 in CD3OD at 500 MHz. 
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Figure S48. NOESY spectrum of 13 in CD3OD at 500 MHz. 
S65 
 
 
Figure S49. 1H NMR spectrum of 16 in CD3OD at 500 MHz. 
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Figure S50. 13C NMR spectrum of 16 in CD3OD at 125 MHz. 
1 9 8 
3 
11 6 
2 10 5 4 12 
14 
15 
16 
13 
17 7 1' 
4' 
5' 2' 3' 
6' 
S67 
 
 
Figure S51. COSY spectrum of 16 in CD3OD at 500 MHz. 
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Figure S52. HSQC spectrum of 16 in CD3OD at 500 MHz. 
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Figure S53. HMBC spectrum of 16 in CD3OD at 500 MHz. 
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Figure S54. NOESY spectrum of 16 in CD3OD at 500 MHz. 
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Figure S55. 1H NMR spectrum of 17 in CD3OD at 500 MHz. 
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Figure S56. 13C NMR spectrum of 17 in CD3OD at 125 MHz. 
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Figure S57. COSY spectrum of 17 in CD3OD at 500 MHz. 
S74 
 
 
Figure S58. HSQC spectrum of 17 in CD3OD at 500 MHz. 
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Figure S59. HMBC spectrum of 17 in CD3OD at 500 MHz. 
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Figure S60. NOESY spectrum of 17 in CD3OD at 500 MHz. 
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Figure S61. Key COSY, HMBC, and NOESY correlations in AZDM glycosides 1113, 16, and 17. 
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Figure S62. HPLCESI-MS chromatogram of erythromycin esterase assay. (A) EIC (m/z 297) for linear form of L-rhamnosyl-10-dml and (B) 
EIC (m/z 296) for linear form of L-rhamnosyl-AZDM. L-rhamnosyl-10-dml (), and L-rhamnosyl-AZDM (11) ().Other possible m/z values for 
the hydrolysed products were extracted (m/z 443 for linear form of L-rhamnosyl-10-dml, m/z 442 for linear form of L-rhamnosyl-AZDM), but no 
significant peaks were observed. 
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Figure S63. HPLCESI-MS chromatogram of simulated gastric fluid (SGF) assay. (A) EIC (m/z 297) for [M+ H]+ of 10-dml and (B) EIC (m/z 
296) for [M + H]+ of AZDM (1). L-rhamnosyl-10-dml (), and L-rhamnosyl-AZDM (11) (). 
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Figure S64. MS spectrum of L-rhamnosyl-10-deoxymethynolide. 
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Figure S65. HPLCESI-MS chromatogram of liver microsomal assay. (A) EIC (m/z 428) for the desmethylated L-rhamnosyl-AZDM and (B) 
EIC (m/z 294) for the hydroxylated L-rhamnosyl-AZDM. Other possible m/z values for the desmethylated (m/z 281) and hydroxylated (m/z 480, 
275) products were extracted, but no significant peaks were observed. 
